Article Text

Download PDFPDF
Severe diarrhoea due to use of P2Y12 inhibitor ticagrelor: a rarely reported adverse event
  1. Khalid Rashid1,
  2. Muhammad Aamir Waheed2,
  3. Hafeez Ur Rehman3 and
  4. Abdel-Naser Elzouki4,5
  1. 1Department of General Medicine, Northampton General Hospital NHS Trust, Northampton, UK
  2. 2Department of Acute Medicine, Northampton General Hospital, Northampton, UK
  3. 3Department of Health Sciences, City University of Science and Information Technology, Peshawar, Pakistan
  4. 4Department of Internal Medicine, Hamad Medical Corporation Department of Medical Education, Doha, Qatar
  5. 5Qatar University College of Medicine, Doha, Qatar
  1. Correspondence to Dr Khalid Rashid; Khalidrashid93{at}


Ticagrelor is a part of dual antiplatelet therapy (DAPT) which has proven benefits in patients with acute coronary syndrome especially in those undergoing percutaneous coronary intervention (PCI). However, like most other drugs, it can lead to undesired and adverse effects such as dyspnoea, easy bruising and gastrointestinal bleeding. We present a case of 70-year-old woman who developed diarrhoea following initiation of DAPT comprising of aspirin and ticagrelor following PCI. After excluding more common causes, it was attributed to ticagrelor administration and completely resolved after it was replaced with another oral antiplatelet agent. On follow-up, the patient reported complete resolution of symptoms.

  • ischaemic heart disease
  • cardiovascular system
  • contraindications and precautions

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors KR contributed to study design, interpretation of data and drafting of the manuscript along with literature review and referencing. MAW contributed in drafting the work and critical revision of the manuscript. HUR participated by writing part of the manuscript including the patient's case history. A-NE gave final approval of the version published.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.